Skip to main content

Vysis Expands Genetic Workstations Sales


DOWNERS GROVE, Ill.--Vysis, a genomic disease management company here specializing in clinical products for evaluating and managing cancer, prenatal disorders, and other genetic diseases, signed agreements in February that will broaden its worldwide coverage to include Mexico, Brazil, and Southern Africa and expand its distributor relationship in Spain. Vysis CEO John Bishop said the company will continue to add distributors to make its clinical and research products and genetic workstations available to clinical labs around the world.

In Mexico and Brazil, Omnichem of Mexico City will distribute Vysis products. In Southern Africa, BDS Diagnostics of Pretoria, South Africa, will handle distribution. Spanish distributor Isaza of Barcelona will market one of Vysis's first clinically approved prenatal products for the early detection of genetic abnormalities associated with mental retardation and other birth defects. Vysis genetic workstations utilize proprietary Fluorescence In Situ Hybridization (FISH) test platforms.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.